SynthesisRenal failure2023
Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
Synthesis in Renal failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta‑analysis.Renal failure · 2024Pooled it
- Graft survival and mortality outcomes after kidney transplant in patients with lupus nephritis: a systematic review and meta-analysis.Renal failure · 2024Pooled it
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- Efficacy and safety of belimumab in lupus nephritis: a real-world retrospective observational study stratified by treatment phase and age.Clinical rheumatology · 2026Observational
- Effectiveness and safety analysis of initial treatment with belimumab in childhood-onset systemic lupus erythematosus.Frontiers in immunology · 2026Article
- Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026Review
- A real-world, triple-cohort study on the effectiveness and safety of telitacicept in immunosuppressant-naïve and refractory lupus nephritis.Frontiers in immunology · 2026Article
- Integrative Use of Belimumab and Individualized Traditional Chinese Medicine in Refractory Pediatric Lupus Nephritis: A Case Report.Journal of inflammation research · 2026Article
- Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus.International journal of molecular sciences · 2025Review
- Systemic Lupus Erythematosus: Ophthalmological Safety Considerations of Emerging and Conventional Therapeutic Agents.International journal of molecular sciences · 2025Review
- BAFF in autoimmune kidney diseases: pathogenic pathways, biomarker potential, and therapeutic horizons.Renal failure · 2025Review
- Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials.Rheumatology (Oxford, England) · 2025Article
- Clinical efficacy and short-term prognosis of belimumab in the treatment of systemic lupus erythematosus in children.American journal of translational research · 2025Article
- Telitacicept versus belimumab in proliferative lupus nephritis.Frontiers in immunology · 2025Article
- Overlapping Tubulointerstitial Lupus Nephritis and Immunoglobulin G4-Related Disease: A Case Report.Cureus · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBelimumab is the first biological agent approved for the treatment of systemic lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not clear. We conducted this meta-analysis and systematic review to compare the efficacy and safety of belimumab with those of conventional therapy for LN.
methodsPubMed, EMBASE, Cochrane Library, Clinical Trials.gov were searched in 31 December 2022 to identify relevant adult human studies reporting effectiveness outcomes of belimumab in patients with LN. Review manager (RevMan 5.4) was used for data analysis with fixed effects model based on heterogeneities.
resultsSix randomized controlled trials (RCTs) were included in the quantitative analysis. A total of 2960 participants were identified. Belimumab plus standard therapy significantly improved total renal response rates (RR, 1.31; 95% CI, 1.11-1.53;
conclusionsThis meta-analysis showed that belimumab plus standard therapy was more effective and had a favorable safety in patients with LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.